Kenji established Bi-Path Bio from his experience as a medical oncologist seeing many incurable cancers. Kenji dedicated himself to make a new medicine for people with cancer over 20 years in both academia and industry. He, however, realized that there are certain cancer types where he does not see much progress since he began his career as a medical oncologist. Pancreatic cancer is the one that he is passionate to develop a new therapy for, and he has a solution to overcome current challenge of pancreatic cancer treatment.

Most recently, Kenji was Chief Medical Officer at Crescendo Biologics where he supported the company’s transition from preclinical to clinical stage immuno-oncology biotech. Prior to Crescendo, he was in the leadership position to execute some late-stage immuno-oncology clinical trials at Roche. Before Roche, he was with Chugai Pharma where he drove the preclinical bispecific immuno-oncology project to clinical phase. He obtained his PhD in molecular oncology at the University of Oxford, and he obtained his MD from Gunma University School of Medicine, Japan.